Peptide LexiconAll compounds

Cortagen (Ala-Glu-Asp-Pro): The 'Brain Cortex' Tetrapeptide Built From Cortexin — What Its 13 PubMed Records Show

Cortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro, designed in St Petersburg from the amino-acid make-up of the brain-extract drug Cortexin. PubMed holds 13 records naming it, 2000 to 2023: rat nerve regeneration, mouse gene arrays and cell cultures. No trial is registered and no controlled study in people was found.

Unlicensed research peptideZero trials on ClinicalTrials.govRat, mouse and cell data

Caroline S · Published 2026-11-19

Length

4 amino acids — C17H26N4O9, molecular weight 430.4 (PubChem CID 18439621)

Sequence

AEDP (Ala-Glu-Asp-Pro), as given in the 2004 Neuro Endocrinol Lett abstract (PMID 15159690) and PubChem's structure for 'cortagen'

Origin

Synthetic; designed at the St Petersburg Institute of Bioregulation and Gerontology from an amino-acid analysis of the brain-cortex extract Cortexin

Last reviewed

2026-11-19

What is it good for?

Its developers call it a brain-cortex tetrapeptide, and it is presented for the brain and nerves. The published work is in rats, mice and cell cultures: faster regrowth of a cut sciatic nerve in rats, changes in gene activity in mouse hearts, and lower markers of oxidative damage in rat brain. No controlled study in people was found, and none is registered.

Illustration: A clear glass test tube with white powder on a light wooden surface in soft light.
Illustration

What it is

Cortagen is a four-residue chain — Ala, Glu, Asp, Pro — made in a laboratory rather than extracted from tissue. Its developers at the St Petersburg Institute of Bioregulation and Gerontology describe it as "obtained by directed synthesis based on amino acid analysis" of Cortexin, a Russian drug made from peptides of animal brain cortex (Anisimov, Khavinson and Anisimov 2004, PMID 15159690). It is one of the short bioregulator peptides of that programme, each named for the organ it is presented for.

Property Value Source
Sequence Ala-Glu-Asp-Pro (AEDP) PMID 15159690; PubChem
Length 4 amino acids —
Formula C17H26N4O9 PubChem CID 18439621
Molecular weight 430.4 PubChem

The family resemblance is in the letters. The heart-labelled Cardiogen is Ala-Glu-Asp-Arg, so Cortagen is Cardiogen with proline in place of arginine. The lung-labelled Bronchogen is Ala-Glu-Asp-Leu. The prostate-labelled Prostamax, Lys-Glu-Asp-Pro, shares Cortagen's last three residues.

What PubMed holds

PubMed's title-and-abstract index held 13 cortagen papers, dated 2000 to 2023, when searched on 2026-11-19; not one carries a clinical-trial tag. By subject:

What was studied Records (examples) People given the peptide?
Nerve regeneration in rats 2000 Bull Exp Biol Med (PMID 11276314); 2002 Dokl Biol Sci (PMID 12134478) No
Gene activity in mouse heart 2004 Neuro Endocrinol Lett (PMID 15159690) No
Oxidative damage and brain ischaemia in rats 2007 (PMID 18239817); 2011 (PMID 21476278) No
Immune signalling in mouse or rat cells 2002 (PMIDs 12447482, 12420072); 2005 (PMID 16224591); 2006 (PMID 17426849) No
Chromatin in cells from elderly people 2004 Bull Exp Biol Med (PMID 15085253); 2023 Georgian Med News (PMID 37042594) No — cells treated in the laboratory

The most specific result is in rats. After the sciatic nerve was cut and sutured, intramuscular cortagen at 10 µg/kg for 10 days increased the growth rate of regenerating fibres by 27% and their conduction velocity by 40% (Turchaninova et al., PMID 11276314). A 2002 follow-up by the same Pavlov Institute authors reports a delayed effect on recovery (PMID 12134478; abstract not available, title read).

The 2004 gene study injected female mice for five days and measured 15,247 transcripts in the heart: 234 clones, 1.53%, changed, matching 110 known genes, with the largest change a 5.42-fold rise (PMID 15159690). It compared the pattern with those of Vilon, Epitalon and melatonin.

What is not established

  • Any effect in people. The 2004 paper's introduction says that "in humans, Cortagen demonstrated a pronounced therapeutic effect" on peripheral nerve recovery, but the abstract gives no study, and no human trial is indexed in PubMed or registered on ClinicalTrials.gov (2026-11-19).
  • Independent replication. The records whose affiliations were read come from St Petersburg institutes or their Georgian collaborators, and V. Khavinson is an author on at least eight of the 13.
  • Safety. No study reports giving it to a person, so nothing is known about its safety in people.
  • That it reaches the brain. None of the records measures whether the peptide crosses into the brain after injection.

Where it stands

Twenty-five years after the sciatic-nerve paper, cortagen's evidence is still rats, mice and dishes of cells, nearly all of it from the laboratories that designed it. Nerve damage, memory complaints and other brain symptoms need a clinician's assessment; this entry sets out the chemistry and the measurements. Related entries: Cortexin, Vilon, Vesugen, Epitalon.

Sources opened 2026-11-19: PubChem (CID 18439621); PubMed E-utilities (search; abstracts of PMIDs 15159690, 11276314, 18239817, 21476278; titles of the other nine); ClinicalTrials.gov API v2.

What the research shows

Speeds nerve regeneration

Turchaninova et al. 2000, Bull Exp Biol Med (PMID 11276314): rats given 10 µg/kg for 10 days after the sciatic nerve was cut and sutured; growth rate +27%, conduction velocity +40%

Changes gene activity in the heart

Anisimov et al. 2004 (PMID 15159690): 15,247 transcripts measured in hearts of mice injected for 5 days; 234 clones (1.53%) changed, matching 110 known genes

Protects the brain from oxidative damage

Kozina 2007 (PMID 18239817) and Zarubina and Shabanov 2011 (PMID 21476278): rats, including a chronic brain-ischaemia model

Helps nerve recovery in people

Stated in the introduction of PMID 15159690 without a citation in the abstract; no human study found in PubMed (2026-11-19)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

None on record: a Drugs@FDA search for cortagen is empty, and no paper in the PubMed set claims a licence (2026-11-19).

Trials

ClinicalTrials.gov: no study of cortagen. The single hit for the word is an unrelated nutrition trial (NCT06852014) matched on spelling (2026-11-19).

Published record

PubMed: 13 records with 'cortagen' in the title or abstract, 2000–2023; 0 tagged as clinical or randomised trials (2026-11-19).

Frequently asked questions

What is Cortagen?

Four amino acids made in the laboratory: Ala-Glu-Asp-Pro, abbreviated AEDP. The St Petersburg bioregulator programme named it for the brain cortex, the tissue whose extract, Cortexin, it was modelled on.

How is Cortagen related to Cortexin?

Its developers say they designed it from the amino-acid composition of Cortexin, a Russian drug made from peptides of animal brain cortex. Cortexin is a mixture; Cortagen is one defined four-amino-acid chain.

What is Cortagen said to be good for?

Its developers describe it as a brain-cortex peptide, and it is presented for the brain and nerves. The studies found are in rats, mice and cell cultures: nerve regrowth after injury, gene activity in the heart and oxidative-damage markers in the brain.

Has Cortagen been tested in humans?

No controlled study in people turned up. One 2004 paper says in its introduction that it helped nerve recovery in humans, but the abstract cites no study, and none is indexed in PubMed or registered on ClinicalTrials.gov.

Is Cortagen the same as Cardiogen?

No, though they differ by one amino acid. Cardiogen is Ala-Glu-Asp-Arg; Cortagen ends in proline instead of arginine: Ala-Glu-Asp-Pro.

Is Cortagen approved?

No regulator's approval appears in Drugs@FDA or in any of the 13 papers. Where it is offered for sale, it is as an unlicensed research chemical.